EXCALIBER RRMM
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Iberdomide, Daratumumab and Dexamethasone VS Daratumumab, Bortezomib, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
What's the purpose of the trial?
The goal of this clinical trial is to find the optimal dose of investigational drug iberdomide in combination with daratumumab and dexamethasone, and to study whether investigational drug iberdomide works in treating relapsed or refractory multiple myeloma when combined with daratumumab and dexamethasone.
Accepting patients
Participating Centers
There are 28 centers participating in this trial. Enter a location below to find the closet center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Bortezomib
- Daratumumab
- Dexamethasone
- Iberdomide
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.